ManishaH.ShahMD

Oncology • Columbus, OH

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shah's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-6529

Fax+1 614-293-9469

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1997
University at BuffaloResidency, Internal Medicine, 1992 - 1995
N.H.L Municipal Medical CollegeClass of 1990

Certifications & Licensure

OH State Medical License 1997 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Start of enrollment: 2001 Apr 01
Completed
Phase 2
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Start of enrollment: 2004 Mar 01
Terminated
Phase 2
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Start of enrollment: 2004 Dec 01
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer Start of enrollment: 2006 Nov 03
Completed
Phase 2
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Start of enrollment: 2010 Oct 28
Completed
Phase 2
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors Start of enrollment: 2012 Nov 19
Completed
Phase 1
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Start of enrollment: 2012 Nov 07
Active, not recruiting
Phase 2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Start of enrollment: 2020 Sep 14
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

154 citations
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger, Barbara Jarzab, Maria E. Cabanillas, Bruce G. Robinson, Furio Pacini
Clinical Cancer Research. 2016-01-01
134 citations
Overall Survival Analysis of EXAM, a Phase III Trial of Cabozantinib in Patients With Radiographically Progressive Medullary Thyroid Carcinoma
Martin Schlumberger, R. Elisei, Stefan P. Müller, Patrick Schöffski, Marcia S. Brose
Annals of Oncology. 2017-11-01
1230 citations
Revised American thyroid association guidelines for the management of medullary thyroid carcinoma
Samuel A. Wells, Sylvia L. Asa, Henning Dralle, Rossella Elisei, Douglas B. Evans
Thyroid. 2015-06-03

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
Neil Saunders, David Strosberg, Jill Onesti, Carl R Schmidt, Manisha Shah, Mary Dillhoff, Lawrence A Shirley, Bhavana Konda, Annals of Surgical Oncology

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Join now to see all

Press Mentions

Cabozantinib Active as Salvage Therapy in Thyroid CancerSeptember 5th, 2017
Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid CancerJune 5th, 2017
Novel Agents Improve MCL Care, Tumor Profiling Key to Further AdvancesOctober 21st, 2015
Join now to see all

Grant Support

Targeting RAF And VEGF Signaling In Thyroid CancerNational Cancer Institute2005–2006
Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2002–2004